title: Effect of antipsychotic drugs and selective dopaminergic antagonists on dopamine-induced facilitatory activity in prelimbic cortical pyramidal neurons. An in vitro study.
abstract: Intracellular recordings were obtained from 119 pyramidal neurons localized in prelimbic cortex, five in the dorsal cingulate cortex, one in the infralimbic cortex, one in the border of prelimbic and cingulate cortex and two in the border of prelimbic and infralimbic cortex. The passive membrane properties of these pyramidal neurons (i.e. resting membrane potential, input membrane resistance, shape of the tetrodotoxin-sensitive action potentials, spike frequency adaptation with a prominent postspike afterhyperpolarization, tetrodotoxin-sensitive inward rectification in the depolarizing direction and the absence of bursting) suggested that they resembled regular spiking or intrinsically bursting pyramidal neurons. Bath application of dopamine (EC50 of 1.8 microM) produced a reversible facilitatory effect on all 119 pyramidal neurons localized in the middle layer of the prelimbic cortex. No consistent change in membrane potential was detected during the application of dopamine. No effect of dopamine was noted on the nine pyramidal neurons that were not localized in the prelimbic cortex. The facilitatory effect of dopamine in prelimbic cortex was concentration dependently antagonized by haloperidol, risperidone, quetiapine, clozapine and by the selective D4 dopaminergic receptor antagonist L-745,870, but not by the selective D2/D3 dopaminergic receptor antagonist (-)-sulpiride. (+)-SCH 23390, which is a selective D1/D5 dopamine receptor antagonist, produced, similarly to dopamine, a facilitatory effect per se, and an additive effect when co-administered with dopamine. These results provide evidence that dopamine has a facilitatory effect specifically on pyramidal neurons localized in the middle layer of prelimbic cortex. Antipsychotic drugs and L-745,870 block this effect of dopamine.
authors.affiliation: Department of Biology, Boehringer-Ingelheim Italia, Milan, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Ceci
authors.forename: A
authors.initials: A
authors.lastname: Brambilla
authors.forename: P
authors.initials: P
authors.lastname: Duranti
authors.forename: M
authors.initials: M
authors.lastname: Grauert
authors.forename: N
authors.initials: N
authors.lastname: Grippa
authors.forename: F
authors.initials: F
authors.lastname: Borsini
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D004298:Dopamine / Q000502:physiology*; D018492:Dopamine Antagonists / Q000494:pharmacology*; D004558:Electric Stimulation; D004594:Electrophysiology; D066298:In Vitro Techniques; D008032:Limbic System / Q000166:cytology / Q000187:drug effects*; D008297:Male; D008564:Membrane Potentials / Q000502:physiology; D018408:Patch-Clamp Techniques; D017397:Prefrontal Cortex / Q000166:cytology / Q000502:physiology; D017966:Pyramidal Cells / Q000166:cytology / Q000187:drug effects*; D051381:Rats; D013268:Stimulation, Chemical
chemical_list: D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D004298:Dopamine